Dayvigo Restarting After Acute Illness: What Clinicians and Patients Need to Know

Why Post-Illness Restart Requires More Than Just Refilling the Prescription

Resuming lemborexant after an acute illness is not a trivial step. The drug's pharmacology creates three distinct vulnerabilities that an illness episode can disturb: hepatic metabolic capacity, co-medication burden, and baseline neuromuscular function.

Lemborexant is metabolized almost entirely by CYP3A4 [1]. Any illness-related change in liver perfusion, hepatocyte inflammation, or co-prescribed drugs that inhibit or induce that enzyme will alter steady-state plasma concentration. A patient who tolerated 10 mg nightly before a hospitalization for community-acquired pneumonia may wake up oversedated if azithromycin or fluconazole prescribed during that admission is still on the medication list.

The Orexin System During Illness

Orexin (hypocretin) neuropeptides promote wakefulness, regulate body temperature, and modulate immune responses [2]. During febrile illness, endogenous orexin tone shifts. Animal studies show interleukin-1-beta suppresses orexin neuronal firing, which partly explains the hypersomnia that accompanies infection [3]. Blocking orexin receptors pharmacologically with lemborexant on top of a virus-suppressed orexin system could, in theory, produce deeper-than-expected sedation while the patient is still recovering.

This does not mean the drug must be withheld during recovery. It means the restart conversation should be deliberate.

What the FDA Label Actually Says

The FDA prescribing information for Dayvigo does not include a specific "restart after illness" protocol, because no dedicated trial has addressed the scenario directly. What the label does specify is [1]:

• Start at 5 mg once nightly, no more than once per night, immediately before bed.
• The 10 mg dose is available for patients who do not respond to 5 mg.
• Use is not recommended in patients with severe hepatic impairment.
• Reduce maximum dose to 5 mg in moderate hepatic impairment (Child-Pugh B).
• Avoid concomitant use with strong or moderate CYP3A4 inhibitors.

Those label provisions translate directly into a post-illness checklist, which is detailed below.

Lemborexant Pharmacokinetics: What Illness Can Disrupt

Understanding the drug's kinetics helps predict exactly which illness-related changes matter most.

Absorption and Distribution

Lemborexant reaches peak plasma concentration (Tmax) in approximately one to three hours after oral dosing [1]. High-fat meals delay Tmax by roughly two hours and reduce Cmax by 23%, a consideration in patients whose appetite and eating schedule are still irregular after illness [1]. The volume of distribution at steady state is approximately 218 liters, indicating extensive tissue distribution.

Hepatic Metabolism and the CYP3A4 Problem

CYP3A4 converts lemborexant into two active metabolites, M4 and M10, which have half-lives of approximately 55 hours and 33 hours, respectively [1]. In healthy volunteers, area under the curve (AUC) for lemborexant increased 4-fold in moderate hepatic impairment and more than 6-fold in severe hepatic impairment compared with normal hepatic function [1]. Acute illnesses that stress the liver, including sepsis, viral hepatitis, severe COVID-19, and even high-dose acetaminophen use during a fever, can transiently shift a patient from Child-Pugh A to B territory.

Getting a basic metabolic panel or liver function tests before restart is a simple, low-cost safeguard.

Renal Impairment: Less Concern

Unlike many sedative-hypnotics, lemborexant does not require dose adjustment for renal impairment, including end-stage renal disease [1]. Kidney-related illness effects are therefore less critical for this drug than hepatic ones.

Drug Interactions Introduced During the Illness Episode

This is the single most overlooked restart risk. Clinicians prescribing lemborexant before the illness often do not see the inpatient or urgent-care medication list. Patients rarely volunteer that information.

Strong CYP3A4 Inhibitors

The FDA label states lemborexant should not be used with strong CYP3A4 inhibitors [1]. Common illness-related prescriptions in this category include:

• Fluconazole (often prescribed for Candida superinfection or oral thrush after antibiotics)
• Clarithromycin (used in atypical pneumonia regimens)
• Ritonavir and other HIV protease inhibitors (relevant in immunocompromised patients)
• Itraconazole or voriconazole (antifungal escalation in immunocompromised hosts)

If any of these agents are still active in the patient's system, lemborexant restart should wait or the dose should be reduced to 5 mg with close monitoring, per label guidance [1].

Moderate CYP3A4 Inhibitors

The label specifies that the maximum lemborexant dose should be reduced to 5 mg when used concurrently with moderate CYP3A4 inhibitors [1]. Illness-era prescriptions that qualify include erythromycin and fluconazole at lower doses. Even a short course that technically ended two days before the restart may still provide measurable enzyme inhibition.

CYP3A4 Inducers

Strong inducers, such as rifampin (used in tuberculosis treatment), carbamazepine, or phenytoin (sometimes initiated during illness-related seizures), significantly reduce lemborexant exposure. Patients on these agents may find that their previously effective dose no longer produces adequate sleep. The label recommends avoiding strong CYP3A4 inducers entirely [1].

CNS Depressants

Acute illness often introduces short-term CNS depressants: opioid cough suppressants, benzodiazepines for procedure anxiety, or antihistamines for allergy-like symptoms. The FDA label warns that combining lemborexant with CNS depressants increases the risk of CNS depression [1]. Confirm all such agents are discontinued before restart.

Clinical Assessment Before Restarting Lemborexant

A structured pre-restart evaluation reduces the risk of adverse events and gives the patient a clear expectation of what to watch for.

Hepatic Status Check

Order or review recent liver function tests (AST, ALT, total bilirubin, albumin). If transaminases are greater than three times the upper limit of normal, consider delaying restart or capping the dose at 5 mg until values normalize. This mirrors the caution framework for moderate hepatic impairment described in the prescribing information [1].

Fall Risk Reassessment

Falls and fall-related injuries are the most clinically significant safety signal associated with orexin receptor antagonists as a class [4]. Post-illness patients frequently have deconditioning, orthostatic hypotension, residual neuromuscular weakness, or dizziness from ototoxic antibiotics. The 2023 American Geriatrics Society Beers Criteria recommends caution with all orexin receptor antagonists in older adults due to CNS adverse effects including somnolence and impaired driving [4].

A quick assessment, asking the patient whether they feel steady on their feet in the morning, is not sufficient for high-risk individuals. Use a validated tool such as the Timed Up and Go (TUG) test for older adults or any patient with a history of falls.

Sleep Pattern During Illness

Ask whether the patient's sleep pattern changed during illness. Bedbound or hospitalized patients often experience circadian disruption, napping excessively during the day and fragmenting nighttime sleep. That disrupted pattern may make the first few nights of restarted lemborexant feel more intense, because sleep pressure may be lower and residual daytime sedation from long-acting metabolites (M4 half-life approximately 55 hours) may accumulate.

The HealthRX clinical team uses a three-gate restart framework for any orexin antagonist after acute illness:

Gate 1 (Pharmacokinetic Gate): Are all strong CYP3A4 inhibitors cleared? Is hepatic function at or near pre-illness baseline?

Gate 2 (Safety Gate): Is the patient's fall risk, orthostatic status, and CNS medication burden acceptable for sedative initiation?

Gate 3 (Timing Gate): Has the primary illness symptom (fever, acute pain, respiratory distress) fully resolved, or at minimum stabilized enough that overnight sedation is appropriate?

All three gates must be open before the previously used dose is restarted at full strength. If Gate 1 or Gate 2 is uncertain, restart at 5 mg regardless of the pre-illness dose.

SUNRISE-1 and What the Evidence Base Tells Us About Lemborexant Safety

No published randomized controlled trial has specifically studied lemborexant restart after acute illness. The best proxy evidence comes from the key trial data and the general pharmacology literature.

SUNRISE-1 Trial Overview

SUNRISE-1 was a Phase 3, randomized, double-blind, placebo-controlled trial published in JAMA Network Open in 2019 (N=1,006) [5]. Participants received lemborexant 5 mg, lemborexant 10 mg, or placebo nightly for 30 days, with a subsequent 7-day double-blind randomized withdrawal period.

The trial's primary endpoint was polysomnographic sleep onset latency on nights 1 and 2. Lemborexant 5 mg reduced latency to persistent sleep by 7.7 minutes versus placebo, and lemborexant 10 mg by 10.9 minutes (both P<0.001) [5]. The SUNRISE-1 investigators concluded: "Lemborexant 5 mg and 10 mg were efficacious in reducing sleep onset and sleep maintenance problems with good tolerability." [5]

Next-Morning Function Data

One of the features that distinguished lemborexant from zolpidem CR in the SUNRISE trials was next-morning driving performance. A dedicated driving simulation study found lemborexant 10 mg caused less next-morning impairment than zolpidem CR 6.25 mg at the same time point post-dose [6]. This is particularly relevant after illness: a patient returning to driving or operating machinery needs to know whether residual effects remain.

The relatively shorter lemborexant parent half-life (approximately 17 to 19 hours) compared with some benzodiazepine receptor agonists supports a more predictable morning clearance profile, though the active metabolites extend the pharmacodynamic window [1].

SUNRISE-2 Long-Term Data

SUNRISE-2 (N=949, 12-month follow-up) confirmed that the safety and efficacy profile was maintained over one year, with no evidence of dose escalation or dependency signaling [7]. This long-term data provides a useful backdrop: patients who tolerated the drug well before an illness episode are returning to a regimen with a well-characterized long-term profile rather than starting fresh.

Special Populations: Who Needs Extra Caution at Restart

Older Adults (Age 65 and Above)

The FDA label and Beers Criteria both single out older adults for heightened vigilance [1][4]. Lemborexant AUC was approximately 45% higher in subjects aged 65 and older compared with younger adults in pharmacokinetic studies [1]. Post-illness, older patients are more likely to have experienced dehydration, nutritional deficits, or temporary hepatic stress. Restart at 5 mg and reassess after two weeks before considering any upward adjustment.

Patients With Obstructive Sleep Apnea (OSA)

The FDA label includes a precaution regarding respiratory depression in patients with compromised respiratory function [1]. A post-illness patient recovering from pneumonia, COVID-19, or any lower respiratory tract infection may have temporarily reduced pulmonary reserve. If OSA is present and CPAP adherence was disrupted during illness, confirm the patient has resumed CPAP before restarting lemborexant.

Patients With Liver Disease

Chronic liver disease patients who experienced an acute illness-related hepatic flare need individualized assessment. If Child-Pugh class worsened from A to B during the illness, the label's 5 mg maximum applies [1]. If the patient is now Child-Pugh C, lemborexant is contraindicated until hepatic function recovers.

Patients With Narcolepsy or Complex Sleep Disorders

Lemborexant's orexin antagonism mechanism is contraindicated in narcolepsy [1]. This remains true regardless of illness status. Patients sometimes receive a narcolepsy or hypersomnia evaluation during a hospitalization. If the evaluation returns a new narcolepsy diagnosis, lemborexant should not be restarted.

Practical Restart Protocol: Step-by-Step

The following protocol synthesizes FDA labeling, pharmacokinetic data, and the HealthRX three-gate framework described above.

Step 1: Medication Reconciliation (Day of Restart Decision)

Pull a complete medication list covering the illness episode. Categorize each agent as a strong CYP3A4 inhibitor, moderate CYP3A4 inhibitor, strong CYP3A4 inducer, or CNS depressant. Use the FDA drug interaction database or a validated clinical tool (e.g., Lexicomp or Epocrates) for classification. Do not rely on patient recall alone.

Step 2: Liver Function Review

Obtain or review liver function tests within the past 14 days. If values are within normal limits and consistent with pre-illness baseline, full-dose restart is appropriate (subject to the other gates). Elevated transaminases without a prior history suggest new hepatic stress and warrant a 5 mg cap.

Step 3: Dose Decision

| Pre-illness dose | Gate 1 clear | Gate 2 clear | Gate 3 clear | Restart dose | |-----------------|-------------|-------------|-------------|-------------| | 10 mg | Yes | Yes | Yes | 10 mg | | 10 mg | No or uncertain | Yes | Yes | 5 mg, reassess in 2 weeks | | 10 mg | Yes | No (fall risk) | Yes | 5 mg, physical therapy referral | | 5 mg | Yes | Yes | Yes | 5 mg | | Any | Any | Any | No (illness active) | Delay restart |

Step 4: Patient Counseling at Restart

Cover the following points explicitly, not just via written handout:

• Take lemborexant only when at least seven to eight hours remain before planned awakening [1].
• Do not drive until next-morning function is confirmed, especially for the first two to three nights after restart.
• Report any new or worsening sleep paralysis, hypnagogic hallucinations, or cataplexy-like symptoms, as these may indicate excessive orexin suppression [1].
• Avoid alcohol, which potentiates CNS depression [1].

Step 5: Follow-Up Check at Two Weeks

Schedule a brief telehealth or in-office check at two weeks. At that visit, review sleep diary data, ask specifically about morning grogginess or falls, and confirm the interaction profile has not changed (e.g., patient still taking an antibiotic started during illness).

Monitoring Metrics After Restart

Tracking outcomes after restart makes the process reproducible and defensible from a documentation standpoint.

The Insomnia Severity Index (ISI), a validated 7-item self-report scale, provides a quantitative baseline [8]. A score above 14 indicates moderate-to-severe insomnia; a score below 8 indicates remission. Re-administer the ISI at two and four weeks post-restart. If scores do not return to pre-illness levels within four weeks and the pharmacokinetic environment is clean (no interactions, normal liver function), consider whether the illness triggered a new or worsened primary insomnia phenotype that merits cognitive behavioral therapy for insomnia (CBT-I) as an adjunct.

CBT-I is recommended as first-line treatment for chronic insomnia by the American College of Physicians, independent of pharmacotherapy [9]. Adding or reinstating CBT-I after a new illness episode can shorten the time to stable sleep without requiring dose increases.

When Not to Restart: Absolute and Relative Contraindications Refreshed by Illness

Certain illness scenarios should prompt a full reassessment of whether lemborexant remains the right choice at all, rather than a simple restart.

New narcolepsy diagnosis: As noted, this is an absolute contraindication [1].

Persistent severe hepatic impairment: If Child-Pugh C persists four or more weeks after illness resolution, lemborexant is contraindicated and an alternative non-sedating approach (CBT-I, melatonin receptor agonist) should be used.

Uncontrolled OSA newly identified during illness: Lemborexant should not be resumed until CPAP or other OSA treatment is established, given the risk of additive respiratory depression.

New CNS structural lesion: If the illness involved meningitis, encephalitis, or a neurological event with a new CNS lesion, insomnia management should be re-evaluated by neurology before any sedative-hypnotic is restarted.